Media Advisory - Oncolytics Biotech® Inc. to Present at Bank of America Merrill Lynch Health Care Conference

Media Advisory - Oncolytics Biotech® Inc. to Present at Bank of America 
Merrill Lynch Health Care Conference 
CALGARY, May 14, 2013 /CNW/ - Dr. Brad Thompson, President and CEO of 
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate 
overview of the Company at the Bank of America Merrill Lynch Health Care 
Conference on Thursday, May 16(th), 2013 at 10:40 a.m. PT. The conference will 
take place from May 14(th) to May 16(th) at Encore at Wynn Las Vegas in Las 
Vegas, NV. 
A live audio link to the webcast presentation is available at: 
http://www.veracast.com/webcasts/baml/healthcare2013/id24500830.cfm or on the 
company's website at www.oncolyticsbiotech.com/presentations.  It is 
recommended that listeners log on 10 minutes in advance of the presentation to 
register and download any necessary software. An audio replay will be 
accessible approximately one hour following the presentation on the Oncolytics 
website. 
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development 
of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical 
program includes a variety of human trials including a Phase III trial in head 
and neck cancers using REOLYSIN(®), its proprietary formulation of the human 
reovirus. For further information about Oncolytics, please visit: 
www.oncolyticsbiotech.com. 
The presentation and webcast times are subject to change. This release and the 
presentation related thereto contain forward-looking statements which involve 
known and unknown risks, delays, uncertainties and other factors not under the 
Company's control and which may cause actual results, performance or 
achievements of the Company to be materially different from the results, 
performance or expectations implied by these forward-looking statements. Such 
risks and uncertainties include, among others, the efficacy of REOLYSIN as a 
cancer treatment, the success and timely completion of clinical studies and 
trials, uncertainties related to the research and development of 
pharmaceuticals and uncertainties related to the regulatory process. Investors 
should consult the Company's quarterly and annual filings with the Canadian 
and U.S. securities commissions for additional information on risks and 
uncertainties relating to the forward-looking statements. Investors are 
cautioned against placing undue reliance on forward-looking statements. The 
Company does not undertake to update these forward-looking statements, except 
as required by applicable laws. 
The Equicom Group Nick Hurst 300 5th Ave. SW, 10th Floor Calgary, Alberta 
T2P 3C4 Tel: 403.218.2835 Fax: 403.218.2830 nhurst@tmxequicom.com  Dian 
Griesel, Inc. Susan Forman 396 West Broadway, 2nd Floor New York, NY 10012 
Tel: 212.825.3210 Fax: 212.825.3229 sforman@dgicomm.com 
SOURCE: Oncolytics Biotech Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/May2013/14/c6577.html 
CO: Oncolytics Biotech Inc.
ST: Alberta
NI: BTC CONF MED  
-0- May/14/2013 10:30 GMT